Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM)

Sundar Jagannath; Dan T. Vogl; Meletios A Dimopoulos; Ajay K. Nooka; Carol Ann Huff; Philippe Moreau; Craig E. Cole; Josh Richter; David Dingli; Ravi Vij; Sascha A. Tuchman; Marc‐Steffen Raab; Katja Weisel; Michel Delforge; David Kaminetzky; Robert F. Cornell; A. Keith Stewart; James E. Hoffman; Kelly Godby; Terri L. Parker; Moshe Levy; Martin Schreder; Nathalie Meuleman; Laurent Frenzel; Mohmad Mohty; Sylvain Choquet; Andrew J. Yee; Maria Gavriatopoulou; Luciano J. Costa; Jatin J. Shah; Carla Picklesimer; Jean‐Richard Saint‐Martin; Lingling Li; Michael Kauffman; Sharon Shacham; Paul G. Richardson; Ajai Chari

doi:10.1016/j.clml.2018.07.149

Related publications

Article2018

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM

Ajai Chari, Dan T. Vogl, Meletios A Dimopoulos, Ajay K. Nooka, Carol Ann Huff, Philippe Moreau, Craig E. Cole, Joshua Richter, David Dingli, Ravi Vij, Sascha A. Tuchman, Marc S. Raab, Katja Weisel, Michel Delforge, David Kaminetzky, Robert F. Cornell, A. Keith Stewart, James E. Hoffman, Kelly Godby, Terri L. Parker, Moshe Levy, Martin Schreder, Nathalie Meuleman, Laurent Frenzel, Mohamad Mohty, Sylvain Choquet, Andrew J. Yee, Maria Gavriatopoulou, Luciano J. Costa, Jatin J. Shah, Carla Picklesimer, Jean‐Richard Saint‐Martin, Lingling Li, Michael Kauffman, Sharon Shacham, Paul G. Richardson, Sundar Jagannath

Article2019

Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).

Paul G. Richardson, Sundar Jagannath, Ajai Chari, Dan T. Vogl, Meletios A Dimopoulos, Philippe Moreau, David Dingli, L. J. Wei, Lingling Li, Shijie Tang, William E. Reichman, Michael Kauffman, Jatin J. Shah, Sharon Shacham, Sagar Lonial

Article2021

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Gabriel Tremblay, Patrick Daniele, Janis L. Breeze, Lingling Li, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Monika Engelhardt, Ajaj Chari, Ajay K. Nooka, Dan T. Vogl, Maria Gavriatopoulou, Meletios A Dimopoulos, Paul G. Richardson, Noa Biran, David S. Siegel, Philip Vlummens, Chantal Doyen, Thierry Façon, Mohamad Mohty, Nathalie Meuleman, Moshe Levy,

Article2020

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma

Paul G. Richardson, Sundar Jagannath, Ajai Chari, Dan T. Vogl, Meletios A Dimopoulos, Philippe Moreau, David Dingli, Lee‐Jen Wei, Joshua Richter, Noa Biran, David S. Siegel, William M. Reichmann, Lingling Li, Shijie Tang, Jean‐Richard Saint‐Martin, Anita Joshi, Michael Kauffman, Jatin J. Shah, Sharon Shacham, Sagar Lonial

Article2016

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Meletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, Michèle Cavo, Michel Delforge, Francesco Di Raimondo, Katja Weisel, Albert Oriol, Markus Hansson, Angelo Vacca, María Jesús Blanchard, Hartmut Goldschmidt, Chantal Doyen, Martin Kaiser, Mario Petrini, Pekka Anttila, Anna Maria Cafro, Reinier Raymakers, Jesús F. San Miguel, Felipe de Arriba, Stefan Knop, Christoph Röllig,